Please click on the ID to see detailed information about each entry.
The total number entries retrieved from this search are| ID | Sequence | Name | Nature of peptide or cargo | Assay | Tissue permeability | Tissue Sample | PUBMED ID |
|---|---|---|---|---|---|---|---|
| 1117 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 64.9±8.8% degraded | Interior skin surface of dermatomed skin (DS) of porcine | 19486932 |
| 1118 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 15±4.1% degraded | Interior skin surface of heat separated epidermis (HSE) of porcine | 19486932 |
| 1119 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 100% degraded | Interior skin surface of full thickness skin (FTS) of porcine | 19486932 |
| 1120 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 87.8±4.4% degraded | Interior skin surface of dermatomed skin (DS) of porcine | 19486932 |
| 1121 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 51.3±6% degraded | Interior skin surface of heat separated epidermis (HSE) of porcine | 19486932 |
| 1194 | Mpr-YFQNCPrG | Desmopressin | It is a peptide hormone that is used chiefly for treatment of enuresis | Radioimmunoassay | 10 ng/ml serum conc. of desmopressin after ~100 min of coated microneedle array application | Lateral skin areas of the thorax of hairless guinea pigs | 15212882 |
| 1195 | Mpr-YFQNCPrG | Desmopressin | It is a peptide hormone that is used chiefly for treatment of enuresis | Radioimmunoassay | 1 ng/ml serum conc. of desmopressin after ~250 min of coated microneedle array application | Lateral skin areas of the thorax of hairless guinea pigs | 15212882 |
| 1196 | Mpr-YFQNCPrG | Desmopressin | It is a peptide hormone that is used chiefly for treatment of enuresis | Radioimmunoassay | 0.8 ng/ml serum conc. of desmopressin after ~350 min of coated microneedle array application | Lateral skin areas of the thorax of hairless guinea pigs | 15212882 |
| 1204 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 1.99 ± 2.04 µg h−1 cm−2 at 100% DC | Human cadaver skin | 14757511 |
| 1205 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 6.47 ± 0.87 µg h−1 cm−2 at 75% DC | Human cadaver skin | 14757511 |
| 1206 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 0.96 ± 0.79 µg h−1 cm−2 at 50% pulsed DC | Human cadaver skin | 14757511 |
| 1207 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 3.33 ± 1.04 µg h−1 cm−2 at 75%+/25%- AC | Human cadaver skin | 14757511 |
| 1208 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 0.15 ± 0.09 µg h−1 cm−2 at 50%+/50%- AC | Human cadaver skin | 14757511 |
| 1218 | I/V-CLe-I/V-K-orn-I/V-fHdN | Bacitracin | Bactericidal antibiotic often used topically. It is a cyclic peptide that contains positively and negatively charged lateral chains at neutral pH and is composed of a mixture of L and D amino acids. | Fluorescein-labeled bacitracin and confocal microscopy, HPLC | Bacitracin Cumulative Amount(µg/cm2)=42.3±3.8 | Human epidermis from abdominal sites of Caucasian females | 12712421 |
| 1219 | I/V-CLe-I/V-K-orn-I/V-fHdN | Bacitracin | Bactericidal antibiotic often used topically. It is a cyclic peptide that contains positively and negatively charged lateral chains at neutral pH and is composed of a mixture of L and D amino acids. | Fluorescein-labeled bacitracin and confocal microscopy, HPLC | Bacitracin Cumulative Amount(µg/cm2)=80.2±4.7 | Human epidermis from abdominal sites of Caucasian females | 12712421 |
| 1220 | I/V-CLe-I/V-K-orn-I/V-fHdN | Bacitracin | Bactericidal antibiotic often used topically. It is a cyclic peptide that contains positively and negatively charged lateral chains at neutral pH and is composed of a mixture of L and D amino acids. | Fluorescein-labeled bacitracin and confocal microscopy, HPLC | Bacitracin Cumulative Amount(µg/cm2)=44.1±4 | Human epidermis from abdominal sites of Caucasian females | 12712421 |
| 1221 | I/V-CLe-I/V-K-orn-I/V-fHdN | Bacitracin | Bactericidal antibiotic often used topically. It is a cyclic peptide that contains positively and negatively charged lateral chains at neutral pH and is composed of a mixture of L and D amino acids. | Fluorescein-labeled bacitracin and confocal microscopy, HPLC | Bacitracin Cumulative Amount(µg/cm2)=82.1±4.4 | Human epidermis from abdominal sites of Caucasian females | 12712421 |
| 1222 | I/V-CLe-I/V-K-orn-I/V-fHdN | Bacitracin | Bactericidal antibiotic often used topically. It is a cyclic peptide that contains positively and negatively charged lateral chains at neutral pH and is composed of a mixture of L and D amino acids. | Fluorescein-labeled bacitracin and confocal microscopy, HPLC | Bacitracin Cumulative Amount(µg/cm2)=52.8±4.4 | Human epidermis from abdominal sites of Caucasian females | 12712421 |
| 1223 | I/V-CLe-I/V-K-orn-I/V-fHdN | Bacitracin | Bactericidal antibiotic often used topically. It is a cyclic peptide that contains positively and negatively charged lateral chains at neutral pH and is composed of a mixture of L and D amino acids. | Fluorescein-labeled bacitracin and confocal microscopy, HPLC | Bacitracin Cumulative Amount(µg/cm2)=95±2.9 | Human epidermis from abdominal sites of Caucasian females | 12712421 |
| 1289 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 57% (32 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1290 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 55% (23 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1291 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 54% (21 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1292 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 56% (20 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1293 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 58% (16 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1294 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 61% (14 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1302 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone | Light and electron microscopy | 10-7 to 10-12 concentrations turned yellow hair brown | Melanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect | 3684299 |
| 1303 | Nle-EHfRWGK | [Nle4, D-Phe7]-alpha-MSH4-11 | Not mentioned | Light and electron microscopy | 10-8 to 10-14 concentrations turned yellow hair brown | Melanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect | 3684299 |
| 1304 | Nle-EHfRWG | [Nle4, D-Phe7]-alpha-MSH4-10 | Not mentioned | Light and electron microscopy | 10-8 to 10-14 concentrations turned yellow hair brown | Melanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect | 3684299 |
| 1306 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7]-α-MSH | the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of mice | Electron microscopy and Light microscopy | Concentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application. | dorsal trunk of mice (C57BL/6JA y) | 3624899 |
| 1307 | Nle-EHfFRWGK | Ac-[Nle4, D-Phe7]-α- MSH4–11-NH2 | the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of mice | Electron microscopy and Light microscopy | Concentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application. | dorsal trunk of mice (C57BL/6JA y) | 3624899 |
| 1308 | Nle-EH-FRWG | Ac-[Nle4, D-Phe7]-α-MSH4–10-NH2 | the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of mice | Electron microscopy and Light microscopy | Concentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application. | dorsal trunk of mice (C57BL/6JA y) | 3624899 |
| 1310 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7)-a-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone | Electron microscopic examination | Minimal effective dose=10-12M. It is transdermally delivered systemically to hair follicles throughout the body to induce follicular melanogenesis. Microscopic examination revealed eumelanin within hair bulbs by 24 hours after topical application of the analogue. | Posterior dorsum of mice (C57BL/6JA y) | 3573985 |
| 1311 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | A superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes. | Frog Skin Bioassay | Percent positive samples of transdermal delivery :65% (15/23) | Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of either black or yellow adult C57BL/6JAy mice killed by cervical dislocation | 2845208 |
| 1312 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | A superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes. | Radioimmunoassay | Percent positive samples of transdermal delivery :85% (11/13) | Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of either black or yellow adult C57BL/6JAy mice killed by cervical dislocation | 2845208 |
| 1313 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | A superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes. | Frog Skin Bioassay | Percent positive samples of transdermal delivery :6.6% (1/15) | Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of mature Sprague Dawley rats. | 2845208 |
| 1314 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | A superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes. | Radioimmunoassay | Percent positive samples of transdermal delivery :11.8% (2/17) | Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of mature Sprague Dawley rats. | 2845208 |
| 1315 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | A superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes. | Frog Skin Bioassay, radioimmunoassay and microscopy | Transdermal delivery of 0.05% | Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of either black or yellow adult C57BL/6JAy mice killed by cervical dislocation | 2845208 |
| 1316 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | A superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes. | Frog Skin Bioassay, radioimmunoassay and microscopy | Transdermal delivery of 0.08% | Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of either black or yellow adult C57BL/6JAy mice killed by cervical dislocation | 2845208 |
| 1329 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 1% aGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1330 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 18.5% YaGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1331 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 3.75% aGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1332 | YaGFL | YGGFL analogue | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | HPLC | 10.75% YaGFL of the parent peptide | Full-thickness hairless mouse skin was excised from the fresh carcasses | 2293206 |
| 1333 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7)-a-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone, a-MSH, in several bioassays | Frog Skin Bioassay | Head and neck(85.7%), Trunk(8.7%),Leg(25%) | Stratum corneum of human skin samples (obtained from freshly excised surgical specimens) | 2155969 |
| 1334 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7)-a-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone, a-MSH, in several bioassays | Radioimmunoassay | Head and neck(78.6%), Trunk(8.8%),Leg(33.3%) | Stratum corneum of human skin samples (obtained from freshly excised surgical specimens) | 2155969 |
| 1405 | rPKPQQwFwLL | Spantide | Effectively prevents the miosis and the disruption of the blood-aqueous barrier consequent to ocular injury. | Radioimmunoassay, HPLC | Systemic uptake corresponds to a serum concentration peak of 4.5*10-9M after 15 minutes | Left eye of pigmented rabbits of either sex and weighing 2-3 kg | 1689665 |
| 1406 | rPKPQQwFwLL | Spantide | Effectively prevents the miosis and the disruption of the blood-aqueous barrier consequent to ocular injury. | Radioimmunoassay, HPLC | Systemic uptake corresponds to a serum concentration peak of 1*10-8M after 15 minutes and intraoccular uptake corresponded to a plateau at 140-150ng/ml for 1-3 hours after completion of application | Left eye of pigmented rabbits of either sex and weighing 2-3 kg | 1689665 |
| 1407 | rPKPQQwFwLL | Spantide | Effectively prevents the miosis and the disruption of the blood-aqueous barrier consequent to ocular injury. | Radioimmunoassay, HPLC | Systemic uptake corresponds to a serum concentration peak of 1*10-7M after 15 minutes and intraoccular uptake corresponded to a plateau at 1.3-1.5µg/ml for 90-240 minutes after completion of application giving an approximate concentration of 10m6 M in the aqueous humor. | Left eye of pigmented rabbits of either sex and weighing 2-3 kg | 1689665 |
| 1478 | YaGFM | [D-ala2]-met-enkephalinamide | A potent opioid peptide | Radioactive determination | Fluid: Tears- degraded peptide=4250pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=0% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1479 | YaGFM | [D-ala2]-met-enkephalinamide | A potent opioid peptide | Radioactive determination | Fluid: Tears- degraded peptide=950pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=0% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1480 | YaGFM | [D-ala2]-met-enkephalinamide | A potent opioid peptide | Radioactive determination | Tissue: Conjunctiva- intact peptide=312pmoles/g tissue, degraded peptide=342pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=0.4% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |